Valuation: ANI Pharmaceuticals, Inc.

Market Cap 1.61B 1.38B 1.29B 1.18B 2.22B 154B 2.25B 15.29B 5.96B 77.61B 6.06B 5.93B 257B P/E 2026 *
15.4x
P/E 2027 * 13.8x
Enterprise Value 1.77B 1.52B 1.42B 1.3B 2.44B 169B 2.47B 16.76B 6.53B 85.04B 6.64B 6.5B 281B EV / Sales 2026 *
1.6x
EV / Sales 2027 * 1.26x
Free-Float
86.72%
Yield 2026 *
-
Yield 2027 * -
1 day-2.55%
1 week-1.55%
Current month-4.91%
1 month-4.80%
3 months-8.96%
6 months-3.11%
Current year-4.55%
1 week 74.81
Extreme 74.81
78.93
1 month 73.27
Extreme 73.27
83.21
Current year 70.15
Extreme 70.15
87.76
1 year 70.15
Extreme 70.15
99.5
3 years 48.2
Extreme 48.2
99.5
5 years 22.31
Extreme 22.31
99.5
10 years 22.31
Extreme 22.31
99.5
Manager TitleAgeSince
Chief Executive Officer 48 2020-09-07
Director of Finance/CFO 55 2016-05-05
Compliance Officer - 2022-02-23
Director TitleAgeSince
Chairman 62 2025-11-23
Director/Board Member 68 2020-08-05
Director/Board Member 66 2020-08-05
Date Insider Type Main position Quantity % Market Cap.
8/13/26 Sell

General Counsel

-500 0.0022%
8/10/26 Sell

Executive/Senior Manager

-3,162 0.0139%
7/29/26 Sell

Chief Financial Officer

-2,850 0.0125%
Change 5-day change 1-year change 3-year change Capi.($)
-2.55%-1.55%-17.32%+23.10% 1.61B
+0.88%+6.38%+76.86%+128.23% 1,119B
+1.07%+3.80%+51.03%+61.48% 651B
+1.20%+6.21%+26.47%+76.45% 468B
+1.02%+5.77%+43.09%+47.70% 374B
+0.85%+4.07%+23.88%+41.58% 302B
+1.26%+6.81%+1.59%+14.67% 259B
+1.88%+5.81%+48.54%+68.52% 238B
+1.59%+2.09%-15.52%-52.29% 208B
+1.87%+5.61%+25.81%+92.42% 181B
Average +0.91%+4.32%+26.44%+50.19% 380.15B
Weighted average by Cap. +1.14%+5.09%+44.28%+72.53%

Financials

2026 *2027 *
Net sales 1.1B 945M 884M 809M 1.52B 106B 1.54B 10.44B 4.07B 53.01B 4.14B 4.05B 175B 1.23B 1.05B 986M 902M 1.69B 118B 1.72B 11.64B 4.54B 59.1B 4.62B 4.52B 195B
Net income 113M 96.92M 90.69M 83.02M 156M 10.83B 158M 1.07B 418M 5.44B 425M 416M 17.99B 125M 107M 100M 91.93M 173M 11.99B 175M 1.19B 463M 6.02B 470M 460M 19.92B
Net Debt 155M 132M 124M 113M 213M 14.8B 216M 1.46B 571M 7.43B 581M 568M 24.59B -69.84M -59.83M -55.98M -51.24M -96.17M -6.68B -97.44M -661M -258M -3.36B -262M -257M -11.1B
Logo ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Employees
970
Date Price Change Volume
26-08-21 US$75.35 -2.55% 379,119
26-08-20 US$77.32 -0.90% 316,455
26-08-19 US$78.02 +1.50% 245,132
26-08-18 US$76.87 +1.14% 286,465
26-08-17 US$76.00 -0.71% 260,823
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
75.35USD
Average target price
108.38USD
Spread / Average Target
+43.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANIP Stock